Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions

Inclusion Criteria: * PAOD and Rutherford classes 2 - 4 (pain-free walking distance \<500 m) * eligible for peripheral revascularization by means of PTA * peripheral lesions in the superficial femoral artery (SFA) and / or the PI-segment of the popliteal artery (A.pop.) * minimum diameter stenosis of ≥70% * treatment length at least 15 cm (lesion length at least 13 cm) * maximum of lesions to be treated should be 2 (all treated lesions should be treated within the randomization to the study group, i.e. either coated balloon catheters or coated stents or bare nitinol stents); in case of two lesions matching the eligibility criteria, the one presenting the worst attributes (length and stenosis degree) should be chosen as target lesion * long diffuse stenosis with or without occlusions may only be divided in separate lesions if non-stenotic (i.e. \<50% stenosis) segments in between the lesions extent to \>2 cm, otherwise vessel segments will be treated as a single extended lesion * eligible for an operative vascular intervention in case of complications during the PTA Exclusion Criteria: * Rutherford class 1,5 or 6 * more than two stenotic lesions in the target vessel requiring treatment * inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to the study lesion * in-stent restenosis of the study lesion * strongly calcified lesions with circumferential presence of calcifications and a lesion calcification length of \>4 cm * reference vessel diameter \<4 mm and \>6 mm * guide wire could not be successfully advanced across the lesion * lesions below the knee requiring treatment * target lesion is located in the PII-segment of the popliteal artery (A.pop.) or within a bypass graft * acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the treatment of the study lesion * potential loss of leg due to critical or acute ischemia * no patent distal run-off vessel * medical reason against double anti-platelet therapy in anti-coagulated patient, e.g., receiving coumarine or conditions which prevent the intake of the double anti-platelet therapy for two months * female patient who is pregnant or lactating * under 18 years of age * patients under administrative or judicial custody (§20 Act on medical Devices, Germany) * expected life span of less than 24 months